Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Julie Plyler is a member of the firm’s corporate practice group and focuses on capital markets and securities transactions in the life sciences industry. She also represents companies in connection with financing transactions.

  • Represented the underwriters in the initial public offering of Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing nalbuphine ER to treat serious neurologically mediated conditions.
  • Represented the underwriters in a global offering of ordinary shares and ADSs of ERYTECH Pharma S.A., a France-based company developing therapies for rare forms of cancer and orphan diseases using a novel technology to encapsulate therapeutic drug substances inside red blood cells.
  • Represented the underwriters in the initial public offering and follow-on offering of American Depositary Shares of Nightstar Therapeutics plc, a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases.
  • Represented the underwriters in various follow-on offerings, including those of UroGen Pharma Ltd., Corbus Pharmaceuticals Holdings, Inc., RedHill BioPharma Ltd. and Nabriva Therapeutics plc.
  • Represented the sales agent in various at-the-market offerings, including those of Corbus Pharmaceuticals Holdings, Inc. and Nabriva Therapeutics plc.
  • Represented Insmed Incorporated in its $259.3 million public offering of common stock.
  • Represented MacroGenics, Inc. in public offerings of over $240 million of common stock.
  • Advises public companies on Exchange Act periodic reporting, proxy statements, Section 16 reporting and securities compliance matters.

Pro Bono

  • Provides legal services and advice to the Jackie Robinson Foundation, a national, not-for-profit organization committed to perpetuating the memory of Jackie Robinson by promoting civic engagement and humanitarian ideals as well as addressing the achievement gap in higher education, in connection with the development of the Jackie Robinson Museum.